About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding Theratechnologies’ growth and the development of Theratechnologies’ pipeline.
Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: demand for EGRIFTA SV® and Trogarzo® will grow in the United States and in Europe, no untoward side effects will be discovered from the long-term use of EGRIFTA SV® and Trogarzo®, none of those products will be subject to a recall, the U.S. Food and Drug Administration will approve our final protocol to initiate our Phase 3 clinical trial in NASH, we will be able to recruit patients for our Phase 3 clinical trial in NASH, we will be able to continue the recruitment of patients for our Phase 1 clinical trial in oncology and results obtained from the conduct of our pre-clinical studies in oncology will be replicated into human subjects.
Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that demand for our products decrease over time, that Trogarzo® is not approved for reimbursement in key European countries, that competition erodes our market share, that our Phase 3 clinical trail in NASH and our Phase 1 clinical trial in oncology do not yield positive results, the effect of which would be to delay or cancel any of those clinical trials, that untoward side effects resulting from the long-term use of our products are discovered, that our intellectual property on tesamorelin is challenged and found to be unenforceable, and that we face product liability litigations.
We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 24, 2021 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 25, 2021 under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.
2
